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geal carcinoma (NPC) and Hodgkin’s disease (HD). We have
shown in the past that LMP1- and LMP2-speciﬁc T-cells can be
activated from EBV-seropositive individuals with adenoviral vec-
tors encoding either an inactive form of LMP1 (dLMP1) or LMP2.
The aim of this study was to construct and characterize an adeno-
viral vector containing dLMP1 and LMP2 (Ad_dLMP1-I-LMP2)
for the generation of LMP1- and LMP2-speciﬁc T cells. Meth-
ods: To evaluate the activity of Ad-dLMP1-I-LMP2 to reactivate
LMP1- and LMP2-speciﬁc CTL, we took advantage of the tro-
pism of Ad5F35 adenoviral vectors, which preferentially transduce
monocytes after incubation of peripheral blood mononuclear cells
(PBMC). Transduced monocytes expressed LMP1 and LMP2, and
reactivated LMP1- and LMP2-speciﬁc T cells, that could be ex-
panded further with autologous LCL transduced with Ad-dLMP1-
I-LMP2. The presence of LMP1- and LMP2-speciﬁc CTL was
determined by tetramer analysis, IFN- ELISPOT assays and
cytotoxicity assays. Results: Stimulation of PBMC with Ad-
dLMP1-I-LMP2 transduced monocytes from 10 HLA-A2, EBV-
seropositive donors resulted in an at least 30 to 100 fold expansion
of LMP1- or LMP2-speciﬁc T-cells as judged by the presence of
HLA-A2 restricted, tetramer positive T-cells. LMP2-speciﬁc re-
sponses were detected in all donors where as LMP1-speciﬁc re-
sponses were found in 7/10 donors. The presence of LMP1- and
LMP2-speciﬁc T-cells was conﬁrmed in a subset of donors with
IFN- ELISPOT assays. In addition, generated LMP1- and
LMP2-CTL killed autologous ﬁbroblasts expressing LMP1 and
LMP2, as well as LCL. Conclusion: The constructed adenoviral
vector, Ad-dLMP1-I-LMP2, is a promising candidate for the ex
vivo generation of LMP1- and LMP2-speciﬁc CTL and may also
be used as a vaccine for the in vivo boosting of adoptively trans-
ferred T cells. Targeting the subdominant LMP antigens ex-
pressed in NPC and HD may improve the efﬁcacy of adoptive
immunotherapy approaches.
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LONG-TERM OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) FOR CML
Goldman, J.M., Sobocinski, K.A., Zhang, M.-J., Klein, J.P.,
Ketelsen, S.W., Giralt, S.A., Horowitz, M.M., Rizzo, J.D. Chronic
Leukemia Working Committee of the Center for International Blood and
Marrow Transplant Research, Milwaukee, WI.
We studied 6548 recipients of allogeneic HCTs performed be-
tween 1978 and 1997 to determine long-term rates of overall
survival, disease-free survival and relapse. As of December 2002,
2710 of the 6548 had survived for 	5 yr, 1926 for 	7 yr, 1044 for
	10 yr, 212 for 	15 yr and 7 for 	20 yr. 2234 patients were alive
and in continuing remission 5 or more years post-HCT. Of these,
the median age at HCT was 34 yrs, 60% had received TBI as part
of their conditioning; 67% had received cyclosporine and metho-
trexate for graft-versus-host disease (GVHD) prophylaxis. Among
patients alive and in remission 5 yrs after HCT, the cumulative
incidences of subsequent relapse at 15 yrs post-HCT were 17%,
15%, 12% and 7% for recipients of sibling transplants in ﬁrst
chronic phase (CP), recipients of sibling transplants not in ﬁrst CP,
recipients of alternative donor transplants in ﬁrst CP and recipients
of alternative donor transplants not in ﬁrst CP respectively. The
latest relapse occurred at 16 yr post HCT. Corresponding survival
rates at 15 years in the patients were 85%, 83%, 80% and 75%. 174
of the 2234 patients surviving in remission at 5 years post HCT
subsequently died; the causes of death were CML (2% of 5 year
survivors), GVHD (1%), second cancer (1%), infection (1.4%),
organ failure (1%) and other (1%). We conclude that remissions
after allogeneic HCT are generally durable. However, after a
high-risk period early post-HCT, there is a low but constant risk of
relapse. Rescue strategies in patients with late relapse may include
donor cell infusions or imatinib, though few data exist regarding
the efﬁcacy of these approaches in this patient group.
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DETECTION OF BCR-ABL EXPRESSION IN HUMAN CML MODEL USING
RADIOLABELED ANALOGUE OF ABL-PROTEIN KINASE INHIBITOR AND
POSITRON-EMISSION TOMOGRAPHY (PET)
Doubrovin, M.1, Beresten, T.1, Veach, D.1, Namavari, M.1,
Balatoni, J.2, Bornmann, W.2, Guelovani, J.2, Larson, S.1 1Memorial
Sloan-Kettering Cancer Center, New York, NY; 2M.D. Anderson Can-
cer Center, Houston, TX.
Introduction of imatinib marked a pivot point in history of
treatment of chronic myelogenic leukemia (CML). Speciﬁc inhi-
bition of bcr-abl kinase interrupts pathologic signal transduction
pathway, terminating tumor growth. To facilitate identiﬁcation of
the patients eligible for imatinib therapy we developed a non-
invasive in vivo imaging technique enabling detection of abl-kinase
expression by PET. A speciﬁc abl-protein kinase inhibitor (PKI)
DV was developed to be radiolabeled. K562—human CML cell
line (overexpressing bcr-abl) and A431—human GBM cell line (low
for abl) were chosen as models. Levels of abl expression were
conﬁrmed by Western blot. In vitro radiotracer accumulation
studies were done with [131I]DV. For in vitro studies subcutaneous
xenograft tumor models were created in contralateral shoulders of
nude rnu/rnu rats. Upon tumor size of 1 cm3, [124I]DL was injected
IV to the rats for 2 sets of scans: 40 Ci for microPET and 200 Ci
for clinical PET-Advance. Acquisition was performed in dynamic
10 min frames for 60 min on microPET and 90 min on PET-
Advance. After image reconstruction ROIs were analyzed for ra-
diotracer dynamics. MicroPET imaging showed accumulation of
[124I]DV in K562 tumor with low background signal in the rest of
the animal. Maximal accumulation in early frames appeared to be
in projection of liver. Imaging on clinical PET-Advance scanner
demonstrated speciﬁc accumulation of [124I]DV radiotracer in hu-
man CML K562 tumor model over 90 min of imaging session. No
accumulation in abl-negative A431 was detected. There was con-
current monophasic clearance of the radiotracer form the circula-
tion. Initial high concentration of the radiotracer in the liver was
gradually clearing out with concomitant increase of bowel signal
demonstrating hepato-biliary clearance. Non-invasive assessment
of bcr-abl expression is feasible by PET-visualization using
[124I]DV, radiolabeled abl-PKI. Detection of bcr-abl expression in
vivo will not only assist identifying treatment target for imatinib
therapy in patients, it might assist monitoring the course of CML
therapy with imatinib. This method can also be used as a screening
option for selection of patients with abl-overexpression in other
types of tumors.
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GM-CSF SECRETING LEUKEMIA CELL VACCINATIONS AFTER ALLOGE-
NEIC NON-MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYN-
DROME OR REFRACTORY ACUTE MYELOID LEUKEMIA
Ho, V.T., Dranoff, G., Pasek, M., MacDonell, R., Cutler, C., Lee, S.J.,
Alyea, E.P., Antin, J.H., Soiffer, R.J. Dana-Farber Cancer Institute,
Boston, MA.
Disease relapse is a frequent cause of treatment failure in patients
undergoing non-myeloablative allogeneic stem cell transplantation
(NST) for advanced myelodysplastic syndrome (MDS) and acute
myeloid leukemia (AML). GVAX, a cancer vaccine composed of
leukemia cells modiﬁed by adenoviral vector mediated gene trans-
fer to secrete GM-CSF, has demonstrated activity in MDS and
AML. We initiated a trial investigating the feasibility and safety of
administering GVAX after allogeneic NST. Patients with MDS-
RAEB or AML not in remission with a donor matched at HLA-
A,B, and DRB1 were eligible. Leukemia blasts were collected for
GVAX generation prior to conditioning. The preparative regimen
consisted of ﬂudarabine 30 mg/m2/d IV days 6 to 3, and
Busulfex 0.8 mg/kg IV q12h  8 doses from days 6 to 3. All
patients received G-CSF mobilized PBSC. GVHD prophylaxis
included tacrolimus starting day3, and methotrexate 5 mg/m2 IV
days 1, 3, 6, 11. GM-CSF (Leukine) 250 mg/m2 SC QD was given
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from day 1 until neutrophil engraftment. GVAX was initiated be-
tween day 30 to 45 if there was adequate hematologic recovery
and no grade II-IV acute GVHD. GVAX was administered ID/SC
qwk 3 doses, then q2wks 3 doses. Taper of tacrolimus began after
vaccine completion. Ten patients (6 URD, 4 MRD) have been trans-
planted to date: 8 AML, 2 MDS/RAEB-2. Seven had circulating
myeloblasts at transplant. GVAX was successfully generated for all 10
patients.Median vaccine cell dose was 1.0 107cells (range, 0.4-1.0
107), and median 24-hr GM-CSF secretion by vaccine cells was 7.25
ng/ml/106cells (range1.0-155.9). Only 4 of 10 patients were able to
start vaccination post transplant. Reasons for failure to initiate vacci-
nation included: death before day 30 (1); acute GVHD (2); insufﬁ-
cient count recovery (3). Among those who receivedGVAX, there was
no GVHD or toxicity attributable to vaccination. Focal inﬁltrates of
lymphocytes were observed in skin biopsies of the vaccination sites.
Two of four vaccinated patients are alive: 1 in CR, and 1 in relapse 5
and 6 months post transplant, respectively. Overall, 7 of 10 patients
have relapsed, 6 before day 100. Although results are preliminary
and the high incidence of early relapse has hindered our ability to
initiate vaccination, GVAX appears to be safe for patients with MDS/
AML after NST. Further cytoreduction prior to NST is necessary for
disease control and improve feasibility of GVAX vaccination in this
very high-risk population.
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TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA
(CML) AND IMATINIB FAILURE AFTER DEVELOPING BCR-ABL KINASE
MUTATIONS WITH ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT)
Jabbour, E., Cortes, J., De Lima, M., Andersson, B., Giralt, S.,
Kantarjian, H., Champlin, R. University of Texas/M.D. Anderson
Cancer Center, Houston, TX.
ASCT is curative for many pts with CML, and may be effective
after imatinib failure. Resistance to imatinib is most often associ-
ated with point mutations in the Bcr-Abl kinase domain. The
outcome of pts with Bcr-Abl kinase mutations after ASCT is not
known. We assessed the outcome of ASCT in 9 pts with CML
(chronic phase [CP]  3, accelerated phase [AP]  3, blast phase
[BP] n  3) harboring 8 different protein kinase mutations. P-loop
mutations were detected in 4 (44%) pts; T315I mutation was
detected in 2 pts (one AP and one CP). Seven male and 2 female
pts, median age of 44 years (range, 26-63 years), received their
ASCT between June 2003 and July 2005. At the time of ASCT,
one pt was in major molecular remission (MMR) (BP, Q252H),
one was in major cytogenetic response (CP, T315I), and 2 were in
complete hematologic response (2 BP, Y253H and E281A). Pre-
parative regimen was busulfan  cyclophosphamide in 7 and ﬂu-
darabine  cyclophosphamide in 2 pts. Donor was fully matched
related in 4 (44%) and unrelated in 5 (56%) pts. Source of stem
cells was peripheral blood and bone marrow in 7 and 2 pts,
respectively. Graft-versus-host disease (GVHD) prophylaxis con-
sisted of tacrolimus and mini methotrexate. All patients engrafted;
there was no treatment-related mortality. Chimerism studies at day
30 and 100 post ASCT were available in 7 pts and were 100% of
donor type. Eight pts achieved a complete molecular remission
(CMR); one pt with a T315I mutation achieved a MMR. Two
(22%) pts (Q252H [BP] and T315I [AP]) relapsed after a median
of 7 months; one of them (T315I) died of disease progression. All
the remaining 7 pts were in CMR for a median of 13 months
(range, 3-20 months). We conclude that ASCT remains an im-
portant salvage option for pts who develop resistance to imatinib
through Bcr-Abl mutations. Early introduction of such strategy
may result in better outcome.
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IN VIVO BIOLUMINESCENCE IMAGING OF ACUTE PROMYELOCYTIC
LEUKEMIA CELL TRAFFICKING AND MOBILIZATION BY AMD3100
Nervi, B.1, Holt, M.1, Rettig, M.P.1, Bridger, G.2, Ley, T.J.1,
DiPersio, J.F.1 1Washington University School of Medicine, St. Louis,
MO; 2AnorMed, Inc., Langley, BC, Canada.
Novel approaches have been developed to mobilize hematopoi-
etic stem cells (HSC) for patients undergoing autologous and allo
transplantation. These strategies may provide insights into im-
proved HSC collection and enhanced egress of leukemic cells and
thus sensitivity to anti-leukemia therapy. CXCR4/SDF-1 axis reg-
ulates the trafﬁcking of normal HSC to and from the bone marrow
(BM). AMD3100 (AMD) speciﬁcally and reversibly blocks SDF-1
binding to CXCR4, and is a promising mobilizing agent currently
in clinical development. We utilized a mouse model of acute
promyelocytic leukemia in which the PML-RAR
 transgene was
knocked into a single allele of the murine cathepsin G locus. We
transduced banked leukemia cells with a dual function reporter
gene that encodes a click beetle red (CBR) luciferase, a biolumi-
nescence imaging (BLI) optical reporter gene, and EGFP for ex
vivo cell sorting (CBR/EGFP). We isolated EGFP cells using a
MoFlo cell sorter, and passaging them in secondary syngeneic
recipients that developed rapidly fatal acute leukemia. Upon intra-
venous (iv) injection of 106 APL cells into syngeneic recipients,
APL rapidly migrated to the BM, with increased BLI signal in the
femurs, spine, ribs, and skull, at 4 days after injection, followed by
spleen inﬁltration and by death due to leukostasis by 14-16 days.
To our knowledge, this represents the only mouse leukemia model
in which leukemia cells home preferentially to the BM in a manner
that is similar to what is seen in human AML. AMD (5 mg/kg) at
the time of APL infusion or bid on days 0-7, had no impact on the
engraftment of either normal HSC or the PML. We observed
rapid mobilization of the APL cells when AMD was administered
11 days after APL injection. 40% of mice that received AMD on
day 11 died 2 to 4 hours after AMD injection as a result of the
rapid and massive mobilization of blasts. Interestingly, CXCR4
expression in mobilized tumor cells decreased from 33  3%
before AMD administration to 19  6%, and 7.8  0.6% after 2
and 12 hours (FACS; P .001). AMD AraC (200 mg/kg) on day
11 prolonged the overall survival of mice, compared with mice
treated only with AraC. In summary, we developed a mouse model
to study the APL cell trafﬁcking, and we have shown leukemia cell
mobilize from the BM into PB after AMD administration. In these
preliminary results we observed that AMD may sensitize APL cells
to AraC. We propose that CXCR4/SDF-1 is a key regulator for
leukemia migration and homing to the BM.
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POSITIVE POSITRON EMISSION TOMOGRAPHY (PET) PRE-AUTOLO-
GOUS STEM CELL TRANSPLANT (ASCT) IN NON-HODGKIN LYMPHOMA
(NHL) DOES NOT PRECLUDE SUCCESSFUL OUTCOME
Bondly, C.C.1, Johnston, P.B.1, Lowe, V.J.2, Ansell, S.M.1,
Inwards, D.J.1, Porrata, L.F.1, Micallef, I.N.1 1Mayo Clinic College of
Medicine, Department of Internal Medicine, Division of Hematology/
Blood & Marrow Transplantation, Rochester, MN; 2Mayo Clinic College
of Medicine, Department of Radiology, Division of Nuclear Medicine,
Rochester, MN.
PET has become an important imaging modality for lymphoma,
and has been reported to be of prognostic signiﬁcance prior to
ASCT for NHL.Methods: To assess the prognostic value of PET
prior to ASCT in NHL, PET pre and post ASCT was prospec-
tively obtained in all NHL patients. From May 2003 to December
2004, 100 patients underwent ASCT for NHL. PET was consid-
ered positive if it had abnormal FDG uptake; CT was positive if it
had areas of lymphadenopathy as deﬁned by the international
response criteria. Results: Median age was 58 (range 17-74); 69%
were male. Patients had received a median of 2 prior chemotherapy
regimens (range 1-9). At relapse, prior to ASCT, the median IPI
was 2 (range 1-5); 31% of patients were stage I or II; 69% were
stage III or IV. Histology included DLBCL 50, transformed NHL
15, mantle cell NHL 11, low-grade NHL 8, T-cell NHL 6,
primary CNS NHL 5, and high grade NHL 5. At ASCT, 43
patients were in CR, 49 in PR, 3 in untreated relapse, and 5 had
resistant disease. The conditioning regimen was BEAM in 89;
Zevalin/BEAM in 10. Pre-ASCT PET was not obtained in 8
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